MPO and metabolic dysfunction-associated steatohepatitis: Accordingly, both MPO-deficiency and MPO pharmacological inhibition reduced liver damage, steatosis and fibrosis, as well as plasma levels of ALT, in a murine model of NASH, which could be explained by the existence of an MPO-dependent pathway for inflammation and apoptosis in this metabolic disease [61].